Paraldehyde

Summary

Paraldehyde (CHEMBL1410743) is an approved small-molecule sedative (ATC N05CC05); indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05CC05
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 132.16 Da · C6H12O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1410743
Name	Paraldehyde
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	31264
ChEBI	CHEBI:27909
ATC	N05CC05
Molecular formula	C6H12O3
Molecular weight	132.16
InChIKey	SQYNKIJPMDEDEG-UHFFFAOYSA-N

SMILES: CC1OC(OC(O1)C)C

IUPAC name: 2,4,6-trimethyl-1,3,5-trioxane

ChEBI definition: A trioxane that is 1,3,5-trioxane substituted by methyl groups at positions 2, 4 and 6.

Pharmacological roles (ChEBI): sedative.

Also known as: FEMA NO. 4010, NSC-9799, Paral, Paraldehyde, Paraldehyde civ, SID29215288, SID50109849, SID170465660, SID144205161, SID144211616, PARALDEHYDE

Patent coverage: 10,053 distinct patent families (18,738 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prelamin-A/C.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	5	Potency	10000	nM	CHEMBL_ACT_3650216

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00116064	PHASE3	COMPLETED	Intranasal Lorazepam Versus Intramuscular Paraldehyde in Paediatric Convulsions

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).